Frankfurt - Delayed Quote EUR

KALA BIO, Inc. (27F0.F)

2.6940

+0.0820

+(3.14%)

As of 9:24:30 AM GMT+2. Market Open.

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

-- Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) -- -- Continuing enrollment into 2Q25; currently targeting topline data in 3Q25 -- -- Raised $10.75 million in private placement financing with participation from SR One, Cormorant Asset Management, Woodline Partners and another life sciences-focused investor -- -- Cash resources of $51.2 million as of December 31, 2024, expected to fund operations into 1Q 2026 -- ARLINGTON, Mass.,

GlobeNewswire 23 days ago

KALA
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

ARLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the TD Cowen 45th Annual Health Care Conference being held in Boston, MA on Wednesday, March 5, 2025 at 11:50 a.m. ET. Management will also be available for one-on-one meetings on Wednesday,

GlobeNewswire last month

KALA
KALA BIO Announces Chief Executive Officer Transition

ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA’s President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of th

GlobeNewswire 2 months ago

KALA
KALA BIO Announces $10,750,000 Private Placement

ARLINGTON, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for the sale, in a private placement, of shares of its common stock and shares of its Series I Convertible Non-Redeema

GlobeNewswire 3 months ago

KALA
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

ARLINGTON, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY on Wednesday, December 4, 2024 at 11:30 a.m. ET. Management w

GlobeNewswire 4 months ago

KALA
KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update

-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline results expected in 2Q 2025 -- -- Initiated five clinical trial sites for the CHASE trial in Argentina; additional sites in Latin America in process, subject to regulatory clearance -- ARLINGTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innov

GlobeNewswire 5 months ago

KALA
KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

ARLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the H.C. Wainwright 4th Annual Ophthalmology Conference, which is being held virtually. A pre-recorded presentation will be made available b

GlobeNewswire 8 months ago

KALA
KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update

-- Closed $12.5 million private placement financing led by SR One with participation from ADAR1 Capital Management and another life sciences-focused investor – -- Cash resources of $54.2 million as of June 30, 2024, together with anticipated funding remaining from CIRM award, expected to fund operations into 4Q 2025 – -- Topline data from Phase 2b CHASE trial of KPI-012 for PCED targeted in Q1 2025 -- ARLINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-st

GlobeNewswire 8 months ago

KALA
KALA BIO Announces $12,500,000 Private Placement

ARLINGTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for the sale, in a private placement, of shares of its common stock and shares of its Series H Convertible Non-Redeema

GlobeNewswire 9 months ago

KALA
KALA BIO to Present at Jefferies Global Healthcare Conference

ARLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Jefferies Global Healthcare Conference being held in New York, NY on Wednesday, June 5, 2024 at 12:30 p.m. ET. Management will also be av

GlobeNewswire 10 months ago

KALA
Wall Street Analysts Just Trimmed Price Target for KALA BIO, Inc. (NASDAQ:KALA)

European stocks started the day on May 21 with a slightly weaker note, marking a retreat from their recent impressive performance, with attention now shifting towards the upcoming earnings report from NVIDIA. The Stoxx 600 index dipped by 0.2%, showing a predominantly negative trend across most sectors, while futures for US equities remained relatively unchanged. […]

Insider Monkey 10 months ago

KALA
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

-- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- -- Evaluating opportunities to expand KPI-012 development into other corneal diseases, including LSCD and to explore KPI-014 in rare inherited retinal diseases -- -- Cash resources of $48.5 million as of March 31, 2024 together with anticipated funding remaining from CIRM award expected to fund operations into 3Q 2025 -- ARLINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- KALA BIO

GlobeNewswire 11 months ago

KALA

Performance Overview

Return	27F0.F	S&P 500 (^GSPC)
YTD	-58.96%	-8.60%
1-Year	-54.68%	+6.00%
3-Year	-92.52%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

KALA BIO, Inc. (27F0.F)

KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

KALA BIO Announces Chief Executive Officer Transition

KALA BIO Announces $10,750,000 Private Placement

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update

KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update

KALA BIO Announces $12,500,000 Private Placement

KALA BIO to Present at Jefferies Global Healthcare Conference

Wall Street Analysts Just Trimmed Price Target for KALA BIO, Inc. (NASDAQ:KALA)

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

Performance Overview